Aims A robust immunohistochemistry (IHC) assay was developed to detect lymphocyte-activation gene 3 (LAG-3) expression by immune cells (ICs) in tumour tissues. LAG-3 is an immuno …

Relatlimab（BMS-986016）是一种抗LAG-3全人源IgG4-κ单克隆抗体，也是临床上开发的首个LAG-3阻断剂。 Relatlimab以高亲和力结合LAG-3并抑制其与MHC-II的结合。 一项重要试验 …

2020年5月25日 · LAG-3 IHC expression was confirmed by in situ hybridization (ACD RNAScope). Positivity was defined as at least one LAG-3+ve or PD-1+ve tumor-infiltrating lymphocyte (TIL) …

2023年6月4日 · This study establishes an association between pre-treatment LAG-3, CD8, STAT1, and LAG-3 + CD8 + tissue expression and responsiveness to monoclonal antibody …

2020年4月8日 · LAG3 is found at high levels on CD8 T cells and CD4 Tregs, with almost universal coexpression of PD-1 and TIM3. Blockade of the PD-1 axis has modest efficacy in diffuse …

2023年12月7日 · LAG3 regulates cancer immunity and is a potential target for ICIs therapy. PD-1 and LAG3 inhibitors may contribute to a better prognosis in MPM.

Aims: A robust immunohistochemistry (IHC) assay was developed to detect lymphocyte-activation gene 3 (LAG-3) expression by immune cells (ICs) in tumour tissues. LAG-3 is an immuno …

2024年12月24日 · Despite the discussed limitations, our study provides an important systematic analysis of the tumor cell intrinsic expression of LAG-3, TIM-3 and their ligands in melanoma …

2022年2月25日 · A robust immunohistochemistry (IHC) assay was developed to detect LAG-3 expression by ICs. The assay was used to stratify patients enrolled in RELATIVITY-047, …

LAG3 expression is assessed as the percentage of immune cells with positive staining that had a morphologic resemblance to lymphocytes within the tumor region (consisting of the tumor, …